-
Capital, M&A & Industry Strategy1 month agoIgA nephropathy, Overton hearing, reverse mergers’ new look — a BioCentury podcast
BIOCENTURY | PRODUCT DEVELOPMENTIGA NEPHROPATHY, OVERTON HEARING, REVERSE MERGERS’ NEW LOOK — A BIOCENTURY PODCASTRecent approvals, validated biomarkers and FDA flexibility have turned IgA nephropathy from...
-
Capital, M&A & Industry Strategy1 month agoai3Bio emerging from stealth to ‘take the gun out of the hands of the immune system’
ai3Bio has emerged from stealth with $48 million in funding and a buzzing platform for targeting T cells in autoimmune disease.
-
Capital, M&A & Industry Strategy1 month agoBayh-Dole Act’s benefits include $3 trillion in U.S. output, report finds
It’s been a long day at the university lab, but the researchers, who have been working on a niche bit of molecular biology research, […] The...
-
Capital, M&A & Industry Strategy1 month agoMore IPO hopefuls aim to echo ADARx’s first-day pop: Public Equity Report
BIOCENTURY | FINANCEMORE IPO HOPEFULS AIM TO ECHO ADARX’S FIRST-DAY POP: PUBLIC EQUITY REPORTFilings by City, Iambic, Retension, and TRexBio fatten the queue
-
Capital, M&A & Industry Strategy1 month agoHow reverse merger-plus-PIPE deals came to rival the IPO path to market
BIOCENTURY | FINANCEHOW REVERSE MERGER-PLUS-PIPE DEALS CAME TO RIVAL THE IPO PATH TO MARKETTighter control over syndicates, timing advantages offer an alternative that’s no longer an...
-
Capital, M&A & Industry Strategy1 month ago
PIPEs power new wave of reverse mergers
BIOCENTURY | FINANCEPIPES POWER NEW WAVE OF REVERSE MERGERSAfter a five-year decline in companies merging to go public, reverse merger-plus-PIPE deals are on the rise in...
-
Capital, M&A & Industry Strategy1 month agoSTAT+: Licensing deals on generic versions of Roche flu drug aimed at preparing for pandemic
With an eye toward pandemic preparedness, a U.N.-backed agency has signed sub-licensing deals related to generic versions of a Roche influenza treatment.
-
Capital, M&A & Industry Strategy1 month agoADARx raises $446M in biotech’s third largest IPO of 2026, City files to go public
Two RNA biotechs, ADARx Pharmaceuticals and City Therapeutics, are taking advantage of the IPO frenzy, which has led to a total of 27 newly public biotechs...
-
Capital, M&A & Industry Strategy1 month agoGenentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecifics
Genentech's agreement with Earendil Labs came the same day its parent company, Roche, inked a cardiometabolic and renal deal with Atavistik Bio for up to $2...
-
Capital, M&A & Industry Strategy1 month agoIndivior ends PAM drug collab with Addex ahead of Supernus merger
Ahead of its upcoming merger with Supernus, Indivior Pharmaceuticals has ended its long-running collaboration with Addex Therapeutics to develop positive allosteric modulators (PAMs).
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure
100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
